Philip A. LoBue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Philip A. LoBue has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
K S Moser
2 shared publicationsKathleen S. Moser
1 shared publication
Latest Publications
- 1 January 2012
- Published by Springer Nature
- p. 1127-1130
HIV, Disseminated Tuberculosis
- 1 May 2005
- Vol. 9 (5) , 501-6
Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002.
A local tuberculosis (TB) control program. To measure trends in isoniazid (INH) and rifampin (RMP) resistance and identify associated factors. Retrospective review. Of 2883 isolates obtained from TB patients reported between 1993 and 2002, 287 (10%) were resistant to INH, 11 (< 1%) were resistant to RMP, and 40 (1%) were resistant to both (multidrug resistance [MDR]). There were no linear trends over time. Eighty-one per cent of patients with INH resistance and 85% with MDR were born outside the United States. Sixty-three per cent of patients with drug resistance and prior TB treatment were treated outside the US. INH resistance was associated with race/ethnicity and prior treatment, RMP resistance with human immunodeficiency virus (HIV) infection, and MDR with non-US birth and prior treatment. Patients with INH- and RMP-susceptible or INH-resistant TB had higher percentages of treatment completion and sputum culture conversion than patients with RMP-resistant or MDR-TB. INH and RMP resistance remained stable between 1993 and 2002. Because most patients with drug resistance were infected or initially treated outside the US, future reductions in drug resistance will depend not only on local and national efforts, but also on the success of global interventions.
- 1 May 2005
- Vol. 9 (5) , 501-6
Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002.
A local tuberculosis (TB) control program. To measure trends in isoniazid (INH) and rifampin (RMP) resistance and identify associated factors. Retrospective review. Of 2883 isolates obtained from TB patients reported between 1993 and 2002, 287 (10%) were resistant to INH, 11 (< 1%) were resistant to RMP, and 40 (1%) were resistant to both (multidrug resistance [MDR]). There were no linear trends over time. Eighty-one per cent of patients with INH resistance and 85% with MDR were born outside the United States. Sixty-three per cent of patients with drug resistance and prior TB treatment were treated outside the US. INH resistance was associated with race/ethnicity and prior treatment, RMP resistance with human immunodeficiency virus (HIV) infection, and MDR with non-US birth and prior treatment. Patients with INH- and RMP-susceptible or INH-resistant TB had higher percentages of treatment completion and sputum culture conversion than patients with RMP-resistant or MDR-TB. INH and RMP resistance remained stable between 1993 and 2002. Because most patients with drug resistance were infected or initially treated outside the US, future reductions in drug resistance will depend not only on local and national efforts, but also on the success of global interventions.
- 1 March 2005
- Vol. 9 (3) , 333-8
Treatment of Mycobacterium bovis infected tuberculosis patients: San Diego County, California, United States, 1994-2003.
A local tuberculosis control program. To examine treatment completion rates of patients with Mycobacterium bovis disease and compare them with those of patients with M. tuberculosis disease. Retrospective review of data from a tuberculosis surveillance computer database. Data from 167 M. bovis patients and 928 M. tuberculosis patients were examined. Rates of treatment completion were not significantly different (78% vs. 82%, chi2 = 1.60, P = 0.174), although death was more frequent among M. bovis patients (15% vs. 7%). The median time to treatment completion was 94 days longer for M. bovis patients. Overall, treatment completion rates of M. bovis and M. tuberculosis patients were comparable, although the death rate was higher for M. bovis patients. The latter finding may be related to a particularly high death rate among HIV-infected M. bovis patients. Therapy duration was longer for M. bovis patients, probably because resistance to pyrazinamide prevented the use of a short-course (6-month) regimen.
- 1 March 2005
- Vol. 9 (3) , 333-8
Treatment of Mycobacterium bovis infected tuberculosis patients: San Diego County, California, United States, 1994-2003.
A local tuberculosis control program. To examine treatment completion rates of patients with Mycobacterium bovis disease and compare them with those of patients with M. tuberculosis disease. Retrospective review of data from a tuberculosis surveillance computer database. Data from 167 M. bovis patients and 928 M. tuberculosis patients were examined. Rates of treatment completion were not significantly different (78% vs. 82%, chi2 = 1.60, P = 0.174), although death was more frequent among M. bovis patients (15% vs. 7%). The median time to treatment completion was 94 days longer for M. bovis patients. Overall, treatment completion rates of M. bovis and M. tuberculosis patients were comparable, although the death rate was higher for M. bovis patients. The latter finding may be related to a particularly high death rate among HIV-infected M. bovis patients. Therapy duration was longer for M. bovis patients, probably because resistance to pyrazinamide prevented the use of a short-course (6-month) regimen.